The Wall Street Journal reports on "a drug-industry financial bonanza," resulting from the additional marketing exclusivity that drug makers have won by starting pediatric trials of adult medicine. The story examines the loopholes that allow the pharmaceuticals giants to protect themselves from generic competition half-a-year and earn extra revenues. The reporter reveals that "makers of generic drugs ... could lose $10.7 billion in sales over 20 years as a result of the six-month extension" for the patents of the brand-name drugs. The story looks at a number of flaws in the regulatory process.
This file is not available for digital download. IRE members may place an order by emailing email@example.com